251 related articles for article (PubMed ID: 26743342)
1. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
2. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
5. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
8. Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy.
Takahashi T; Arora M; Okoev G; DeFor TE; Weisdorf DJ; MacMillan ML
Transplant Cell Ther; 2021 Aug; 27(8):667.e1-667.e5. PubMed ID: 34077812
[TBL] [Abstract][Full Text] [Related]
9. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
[TBL] [Abstract][Full Text] [Related]
10. Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study.
Balduzzi A; Dalle JH; Wachowiak J; Yaniv I; Yesilipek A; Sedlacek P; Bierings M; Ifversen M; Sufliarska S; Kalwak K; Lankester A; Toporski J; Di Maio L; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2197-2210. PubMed ID: 31319153
[TBL] [Abstract][Full Text] [Related]
11. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Saad A; Lamb L; Wang T; Hemmer MT; Spellman S; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Agrawal V; Aljurf M; Beitinjaneh AM; Bhatt VR; Buchbinder D; Byrne M; Cahn JY; Cairo M; Castillo P; Chhabra S; Diaz MA; Farhan S; Floisand Y; Frangoul HA; Gadalla SM; Gajewski J; Gale RP; Gandhi M; Gergis U; Hamilton BK; Hematti P; Hildebrandt GC; Kamble RT; Kanate AS; Khandelwal P; Lazaryan A; MacMillan M; Marks DI; Martino R; Mehta PA; Nishihori T; Olsson RF; Patel SS; Qayed M; Rangarajan HG; Reshef R; Ringden O; Savani BN; Schouten HC; Schultz KR; Seo S; Shaffer BC; Solh M; Teshima T; Urbano-Ispizua A; Verdonck LF; Vij R; Waller EK; William B; Wirk B; Yared JA; Yu LC; Arora M; Hashmi S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1875-1883. PubMed ID: 31085303
[TBL] [Abstract][Full Text] [Related]
12. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
Qayed M; Wang T; Hemmer MT; Spellman S; Arora M; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Aljurf M; Ayas M; Bitan M; Cairo M; Choi SW; Dandoy C; Delgado D; Gale RP; Hale G; Frangoul H; Kamble RT; Kharfan-Dabaja M; Lehman L; Levine J; MacMillan M; Marks DI; Nishihori T; Olsson RF; Hematti P; Ringden O; Saad A; Satwani P; Savani BN; Schultz KR; Seo S; Shenoy S; Waller EK; Yu L; Horowitz MM; Horan J
Biol Blood Marrow Transplant; 2018 Mar; 24(3):521-528. PubMed ID: 29155316
[TBL] [Abstract][Full Text] [Related]
13. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.
Kharfan-Dabaja MA; Sheets K; Kumar A; Murthy HS; Nishihori T; Tsalatsanis A; Mina A; Mathews J; Ayala E; Chavez J; Perez LE; Betts BC; Anasetti C; Pidala J
Br J Haematol; 2018 Mar; 180(6):854-862. PubMed ID: 29345306
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of nonrelapse mortality post T-cell-replete haploidentical stem cell transplantation in patients with recurrence of acute graft-versus-host disease.
Peng B; Dou L; Yang J; Wang L; Li F; Gao X; Wang S; Jin X; Wang L; Jia M; Wang S; Li Y; Liu D
Hematol Oncol; 2022 Oct; 40(4):743-751. PubMed ID: 35385135
[TBL] [Abstract][Full Text] [Related]
15. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
16. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.
Arai Y; Kanda J; Nakasone H; Kondo T; Uchida N; Fukuda T; Ohashi K; Kaida K; Iwato K; Eto T; Kanda Y; Nakamae H; Nagamura-Inoue T; Morishima Y; Hirokawa M; Atsuta Y; Murata M;
Bone Marrow Transplant; 2016 Jan; 51(1):96-102. PubMed ID: 26367230
[TBL] [Abstract][Full Text] [Related]
18. [Effect of graft-versus-host disease on relapse and survival in 100 patients after allogeneic hematopoietic stem cell transplantation].
Deng XR; Ren HY; Cen XN; Wang LH; Liang ZY; Wang WS; Qiu ZX; Ou JP; Xu WL; Wang MJ; Li Y; Yin Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):994-8. PubMed ID: 19698246
[TBL] [Abstract][Full Text] [Related]
19. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
20. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Auletta JJ; Badawy SM; Bhatt N; Bhatt VR; Cahn JY; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Gale RP; Hashem H; Hashmi S; Hematti P; Hong S; Hossain NM; Inamoto Y; Lekakis LJ; Modi D; Patel S; Sharma A; Solomon S; Couriel DR
Transplant Cell Ther; 2022 Oct; 28(10):712.e1-712.e8. PubMed ID: 35863740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
